Is IMNM or BBOT more profitable?

BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% BridgeBio Oncology Therapeutics N/A N/A N/A

Does the media refer more to IMNM or BBOT?

In the previous week, Immunome had 2 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 3 mentions for Immunome and 1 mentions for BridgeBio Oncology Therapeutics. Immunome's average media sentiment score of 1.03 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BBOT or NRIX?

In the previous week, Nurix Therapeutics had 19 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 20 mentions for Nurix Therapeutics and 1 mentions for BridgeBio Oncology Therapeutics. Nurix Therapeutics' average media sentiment score of 0.26 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer NKTR or BBOT?

In the previous week, Nektar Therapeutics and Nektar Therapeutics both had 1 articles in the media. Nektar Therapeutics' average media sentiment score of 1.30 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BBOT or VCEL?

In the previous week, Vericel had 26 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 27 mentions for Vericel and 1 mentions for BridgeBio Oncology Therapeutics. Vericel's average media sentiment score of 0.51 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BridgeBio Oncology Therapeutics (BBOT) Competitors

$8.78 -0.18 (-2.01%)

Closing price 04:00 PM Eastern

Extended Trading

$8.81 +0.03 (+0.34%)

As of 04:10 PM Eastern

Compare

BBOT vs. IMNM, RARE, NRIX, NKTR, and VCEL

Should you buy BridgeBio Oncology Therapeutics stock or one of its competitors? MarketBeat compares BridgeBio Oncology Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BridgeBio Oncology Therapeutics include Immunome (IMNM), Ultragenyx Pharmaceutical (RARE), Nurix Therapeutics (NRIX), Nektar Therapeutics (NKTR), and Vericel (VCEL). These companies are all part of the "biotechnology" industry.

How does BridgeBio Oncology Therapeutics compare to Immunome?

Immunome (NASDAQ:IMNM) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

BridgeBio Oncology Therapeutics has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$4.02M	728.30	-$212.39M	-$2.38	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A

Immunome has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

In the previous week, Immunome had 2 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 3 mentions for Immunome and 1 mentions for BridgeBio Oncology Therapeutics. Immunome's average media sentiment score of 1.03 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunome currently has a consensus target price of $33.17, indicating a potential upside of 28.45%. BridgeBio Oncology Therapeutics has a consensus target price of $24.80, indicating a potential upside of 182.46%. Given BridgeBio Oncology Therapeutics' higher probable upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

44.6% of Immunome shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

Summary

BridgeBio Oncology Therapeutics beats Immunome on 8 of the 14 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Ultragenyx Pharmaceutical?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Ultragenyx Pharmaceutical had 16 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 17 mentions for Ultragenyx Pharmaceutical and 1 mentions for BridgeBio Oncology Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.39 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

BridgeBio Oncology Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A
Ultragenyx Pharmaceutical	$673M	3.78	-$575M	-$5.84	N/A

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BridgeBio Oncology Therapeutics currently has a consensus target price of $24.80, indicating a potential upside of 182.46%. Ultragenyx Pharmaceutical has a consensus target price of $57.82, indicating a potential upside of 123.95%. Given BridgeBio Oncology Therapeutics' higher probable upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-43.78%

Summary

BridgeBio Oncology Therapeutics beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Nurix Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

In the previous week, Nurix Therapeutics had 19 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 20 mentions for Nurix Therapeutics and 1 mentions for BridgeBio Oncology Therapeutics. Nurix Therapeutics' average media sentiment score of 0.26 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BridgeBio Oncology Therapeutics presently has a consensus price target of $24.80, indicating a potential upside of 182.46%. Nurix Therapeutics has a consensus price target of $34.00, indicating a potential upside of 34.81%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

BridgeBio Oncology Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A
Nurix Therapeutics	$36.77M	71.19	-$264.46M	-$3.45	N/A

Summary

BridgeBio Oncology Therapeutics beats Nurix Therapeutics on 9 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

Nektar Therapeutics presently has a consensus target price of $150.00, suggesting a potential upside of 104.22%. BridgeBio Oncology Therapeutics has a consensus target price of $24.80, suggesting a potential upside of 182.46%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Nektar Therapeutics and Nektar Therapeutics both had 1 articles in the media. Nektar Therapeutics' average media sentiment score of 1.30 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

BridgeBio Oncology Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.63M	44.61	-$164.08M	-$8.42	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BridgeBio Oncology Therapeutics beats Nektar Therapeutics on 8 of the 13 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Vericel?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

In the previous week, Vericel had 26 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 27 mentions for Vericel and 1 mentions for BridgeBio Oncology Therapeutics. Vericel's average media sentiment score of 0.51 beat BridgeBio Oncology Therapeutics' score of 0.00 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Vericel has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A
Vericel	$306.30M	7.48	$16.52M	$0.47	95.21

BridgeBio Oncology Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Vericel has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Vericel has a net margin of 7.91% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.91% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
Vericel	7.91%	6.91%	5.02%

BridgeBio Oncology Therapeutics currently has a consensus price target of $24.80, suggesting a potential upside of 182.46%. Vericel has a consensus price target of $58.40, suggesting a potential upside of 30.50%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Vericel	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Vericel beats BridgeBio Oncology Therapeutics on 10 of the 15 factors compared between the two stocks.

Get BridgeBio Oncology Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBOT vs. The Competition

Export

Metric	BridgeBio Oncology Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$703.34M	$3.61B	$6.93B	$12.84B
Dividend Yield	N/A	3.77%	2.60%	9.78%
P/E Ratio	-4.28	7.68	281.16	25.43
Price / Sales	N/A	1,229.81	577.53	82.47
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	1.71	17.03	12.86	6.06
Net Income	-$134.04M	-$12.50M	$3.49B	$348.34M
7 Day Performance	3.29%	2.90%	2.64%	3.03%
1 Month Performance	4.40%	-4.49%	-2.64%	-3.04%
1 Year Performance	N/A	54.14%	76.00%	20.65%

BridgeBio Oncology Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBOT BridgeBio Oncology Therapeutics	2.0845 of 5 stars	$8.78 -2.0%	$24.80 +182.5%	N/A	$703.34M	N/A	N/A	N/A
IMNM Immunome	3.2851 of 5 stars	$22.76 -1.4%	$33.17 +45.7%	+135.2%	$2.58B	$4.02M	N/A	40	Positive News Insider Trade
RARE Ultragenyx Pharmaceutical	3.7297 of 5 stars	$24.91 -4.3%	$58.41 +134.5%	-13.8%	$2.45B	$673M	N/A	1,371	News Coverage Earnings Report Analyst Forecast
NRIX Nurix Therapeutics	2.5957 of 5 stars	$23.21 -1.6%	$34.00 +46.5%	+122.1%	$2.41B	$36.77M	N/A	300	News Coverage Analyst Forecast Insider Trade
NKTR Nektar Therapeutics	2.9953 of 5 stars	$70.67 -1.1%	$150.00 +112.3%	+224.0%	$2.39B	$55.63M	N/A	220	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBOT) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. IMNM, RARE, NRIX, NKTR, and VCEL

How does BridgeBio Oncology Therapeutics compare to Immunome?

Summary

How does BridgeBio Oncology Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does BridgeBio Oncology Therapeutics compare to Nurix Therapeutics?

Summary

How does BridgeBio Oncology Therapeutics compare to Nektar Therapeutics?

Summary

How does BridgeBio Oncology Therapeutics compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. IMNM, RARE, NRIX, NKTR, and VCEL

How does BridgeBio Oncology Therapeutics compare to Immunome?

Which has higher valuation & earnings, IMNM or BBOT?

Which has more volatility and risk, IMNM or BBOT?

Does the media refer more to IMNM or BBOT?

Do analysts recommend IMNM or BBOT?

Do institutionals & insiders believe in IMNM or BBOT?

Is IMNM or BBOT more profitable?

Summary

How does BridgeBio Oncology Therapeutics compare to Ultragenyx Pharmaceutical?

Does the media refer more to BBOT or RARE?

Which has more volatility and risk, BBOT or RARE?

Which has preferable earnings & valuation, BBOT or RARE?

Do institutionals and insiders have more ownership in BBOT or RARE?

Do analysts prefer BBOT or RARE?

Is BBOT or RARE more profitable?

Summary

How does BridgeBio Oncology Therapeutics compare to Nurix Therapeutics?

Is BBOT or NRIX more profitable?

Does the media refer more to BBOT or NRIX?

Do institutionals & insiders believe in BBOT or NRIX?

Do analysts recommend BBOT or NRIX?

Which has more risk and volatility, BBOT or NRIX?

Which has preferable valuation and earnings, BBOT or NRIX?

Summary

How does BridgeBio Oncology Therapeutics compare to Nektar Therapeutics?

Is NKTR or BBOT more profitable?

Do analysts prefer NKTR or BBOT?

Does the media prefer NKTR or BBOT?

Which has more risk & volatility, NKTR or BBOT?

Which has stronger earnings and valuation, NKTR or BBOT?

Do insiders and institutionals hold more shares of NKTR or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to Vericel?

Does the media refer more to BBOT or VCEL?

Do insiders & institutionals have more ownership in BBOT or VCEL?

Which has preferable earnings and valuation, BBOT or VCEL?

Which has more risk and volatility, BBOT or VCEL?

Is BBOT or VCEL more profitable?

Do analysts prefer BBOT or VCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools